AUTHORS
Eolia Brissot, MD, PhD, Thibeault Ferhat Berland, PhD2, Raynier Devillier, PhD3, Alexander Kulagin4, Anna Maria Raiola, MD5, Jan Vydra6, Simona Sica7, Jurjen Versluis Sr, MD, PhD8, Mi Kwon, MD,PhD9, Francis Ayuketang Ayuk, MD10, Montserrat Rovira11, Yener Koc, MD12, Linde Morsink13, Maija Itälä-Remes14, Peter Von Dem Borne15, Martin Carre, MD16, Johanna Tischer17, Alexandros Spyridonidis18, Francesco Saraceni, MD19, Frederic Baron, MD20, Arnon Nagler I, MD21, Mohamad Mohty, MD, PhD22, Jaime Sanz, MD, PhD23, Fabio Ciceri24
AFFILIATIONS
1 Sorbonne University, CRSA INSERM UMRS_938, Service d'Hématologie clinique et thérapie cellulaire, Hôpital Saint-Antoine, APHP,, Paris, France
2 EBMT Paris study office, Paris, France
3 Department of Clinical Hematology, Institut Paoli-Calmettes, Université Aix-Marseille, Marseille, France
4 RM Gorbacheva Research Institute, Pavlov University, Saint Peterburg, Russian Federation
5 Azienda Ospedaliera Metropolitana-IRCCS Ospedale Policlinico, San Martino, Genova, Italy
6 Institute of Hematology and Blood Transfusion, Prague, Czech Republic
7 Dipartimento di Scienze di Laboratorio ed Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy. Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Roma, Italy
8 Erasmus MC Cancer Institute, Rotterdam, Netherlands
9 Hospital Gregorio Marañón, Madrid, Spain
10 Department of Stem Cell Transplantation (SCT), University Medical Center Hamburg-Eppendorf (UKE),, Hamburg, Germany
11 BMT Unit, Haematology Department, Institute of Haematology and Oncology, IDIBAPS, Hospital clinic, University of Barcelona, Barcelona, Spain
12 Medicana International Hospital Istanbul, Istanbul, Turkey
13 Rijks Universiteit Groningen (RUG), Department of Hematology, University Medical Center Groningen, Groningen, Netherlands
14 Turku University Hospital, Turku, Finland
15 Leiden University Hospital, Leiden, Netherlands
16 Department of Hematology, Grenoble University Hospital, Grenoble, France
17 Ludwig Maximilians University of Munich, Klinikum der Universitaet Muenchen-Grosshadern, Munich, Germany
18 Department of Internal Medicine, Bone Marrow Transplantation Unit, University Hospital of Patras, Patras, Greece
19 Hematology Department, University Hospital, Ancona, Italy
20 University and Centre Hospitalier Universitaire of Liège, Liège, Belgium
21 Hematology Division, Chaim Sheba Medical Center and Tel Aviv University, Tel-Hashomer, Ramat-Gan, Israel
22 Sorbonne University, CRSA INSERM UMRS_938, Service d'Hématologie clinique et thérapie cellulaire, Hôpital Saint-Antoine, APHP,, Paris, France
23 Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia Departament de Medicina Universitat de Valencia, CIBERONC, Instituto Carlos III, Valencia, Spain
24 Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Hospital, Milano, Italy
ABSTRACT
Introduction
The introduction of post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis was initially developed in the setting of HLA-haploidentical (Haplo) stem cell transplantation (HCT). This strategy was instrumental in enabling the widespread adoption of Haplo HCT. The expanding use of PTCy has challenged the traditional paradigm that HLA-matched sibling donors (MSD) consistently provide superior outcomes compared with matched unrelated donors (MUD), or mismatched unrelated donors (MMUD) or Haplo donors (HaploD). Administered after graft infusion, post-transplant cyclophosphamide (PTCy) is thought to promote immune tolerance while preserving graft-versus-leukemia activity. Therefore, we investigated temporal trends in the use of PTCy and evaluated whether changes in transplantation practice were associated with improvements in clinical outcomes.
Methods
First, all adult patients who underwent a first allo-HCT for AML between 2012 and 2022 with a MSD, a MUD, a MMUD or a HaploD, and received PTCy as GVHD prophylaxis, and were registered in the EBMT registry, were included. To compare the outcomes over time, the study period was divided into 3 time periods : 2012-2015 (P1)/2016-2019 (P2)/2020-2022 (P3). Secondly, to compare outcomes, we focused on patients in first complete remission (CR).
Results
A total of 6716 patients were included : 1027 in P1, 2662 in P2 and 3027 in P3. The median follow-up of the whole cohort was 3.1 years (y) (3-3.1), in P1 7.7y (6.9-8.2), in P2 5y (4.7-5), and in P3 2.5y (2.3-2.6). Although the use of PTCy remains predominant in Haplo-HCT, its use has increased markedly over time, particularly in MMUD transplantation (5.1% to 11.5%, p<0.001). Between P1 and P3, peripheral blood (PB) became the predominant stem cell source, increasing from 55.5% to 89.6% (p<0.001). The use of PTCy also evolved over time according to disease status. During P1, patients with AML in CR1 accounted for 52.9% of transplants, while those with active disease and AML ≥ second CR represented 29.9% and 17.2%, respectively ; during P3, these proportions changed to 65.6%, 18.3%, and 16.1% respectively (p<0.001).
We, then, restricted analysis on the 4408 transplanted patients in first CR: 543 in P1, 1732 in P2, and 2133 in P3. Baseline characteristics were largely comparable across periods with respect to karnofsky performance status, patient sex, donor sex and ELN risk category. However, patients became progressively older (p<0.001) whereas donor age decreased over time (p<0.003). Myeloablative conditioning remained the predominant conditioning over time. In P1, at 2 y, overall survival (OS), leukemia-free survival (LFS), GVHD-free, relapse-free survival (GFRS), relapse incidence (RI) and non-relapse mortality were 63.7%, 57.9%, 43.3%, 23% and 18.8% respectively ; and in P3, 68.3%, 62.3%, 51.8%, 21.3% and 16.1% respectively. In multivariate analysis, using P3 as the reference category compared with P1 , clinical outcomes improved progressively over time (OS HR :1.14, p<0.001, LFS HR :1.4, p<0.00, GRFS HR : 1.59, p<0.001, RI HR: 1.29, p=0.036, NRM HR : 1.58, p=0.001). Period of time of transplant was also a prognostic factor for chronic(c) GVHD and extensive cGVHD with a significantly reduced cumulative incidence across the three studied time periods (HR: 1.69, p<0.001 and HR: 4.03, p<0.001, respectively). Beyond calendar period, several variables were independently associated with transplant outcomes. Compared with MSD and MUD, HaploD transplantation was associated with improved OS and GRFS, lower NRM, and a lower incidence of cGVHD compared with MUD. Older recipient age was associated with inferior OS, LFS and GRFS, and higher NRM. Older donor age was independently associated with inferior OS and GRFS, higher NRM, and increased risks of grade II–IV aGVHD, cGVHD and extensive cGVHD. Finally, compared with PB, BM grafts were associated with lower incidences of cGVHD and extensive cGVHD.
Conclusions
The use of PTCy for GVHD prophylaxis has dramatically increased since 2012. Although it remains predominantly used in haploidentical transplantation, its use has also expanded substantially to other donor types. Outcomes improved during the decade in parallel with the increasing adoption of PTCy and evolving transplantation practice. Stem cell source and donor age were independently associated with transplant outcomes and should be considered during donor selection.
DISCLOSURES
Eolia Brissot, MD, PhD: No relevant conflicts of interest to declare.